journal article·2024-06-22Open access

Serum Profiling of Proinflammatory Mediators in Inflammatory Bowel Disease: Indication for Use in Differential Diagnosis

Aleksandra Górecka, Grzegorz Wisowski, Yoana Kisselova-Kaneva, Diana Ivanova, Paweł Olczyk, Katarzyna Komosinska-Vassev

Applied Sciences· Volume 14· Issue 13

Abstract

Inflammatory Bowel Disease (IBD) is a group of chronic intestinal diseases, among which Crohn’s disease (CD) and ulcerative colitis (UC) represent the two main types. The differential diagnosis of these two disorders is often a significant challenge, as there is a lack of specific and non-invasive biomarkers. In this study, we assessed the serum profile of proinflammatory mediators (E- and P-selectin, CCL2, IL-1α, IL-12p70, TNF-α) in patients with IBD to identify biomarkers helpful in the differential diagnosis of CD and UC. The conducted statistical analyses revealed a significant increase in E-selectin, P-selectin, IL-1α, and IL-12p70 levels in the serum of CD patients compared to UC. The performed ROC curve analysis identified moderate values of E-selectin (AUC 0.752), P-selectin (AUC 0.733), and IL-1α (AUC 0.731) in differentiating CD from UC, while IL-12p70 presented a satisfactory value (AUC 0.695). Simultaneous measurements of each biomarker with serum calprotectin improved the ability of E-selectin (AUC 0.752 vs. 0.829), P-selectin (AUC 0.733 vs. 0.75), IL-1α (AUC 0.731 vs. 0.778), and IL-12p70 (AUC 0.695 vs. 0.714) to differentiate CD from UC. Moreover, we identified a significant relationship between the concentration of CCL2 (r = 0.566, p < 0.005) and TNF-α (r = 0.431, p < 0.05) and the disease activity expressed as the Mayo score in the UC group. We also identified a significant relationship between the concentration of E-selectin (r = 0.372, p < 0.05), CCL-2 (r = 0.55, p < 0.05), IL-1α (r = 0.637, p < 0.005), and TNF-α in the group of patients with UC. Another significant correlation in the UC group was noted in the case of E-selectin and IL-12p70 (r = 0.542, p < 0.05), as well as between IL1-α and P-selectin (r = 0.514, p < 0.05). The results obtained in this study indicate the potential use of E-selectin, P-selectin, IL-1α, and IL-12p70 serum profiles in differentiating CD from UC. Regarding the significant relationship of CCL2 and TNF-α with the Mayo score, these two biomarkers might be useful in assessing and monitoring the disease activity during UC.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Inflammatory Bowel Disease · Cytokine Signaling Pathways and Interactions · S100 Proteins and Annexins

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Clinical Chemistry and Laboratory Diagnostics, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, 40-055 Katowice, Poland

Department of Biochemistry, Molecular Medicine and Nutrigenomics, Faculty of Pharmacy, Medical University “Prof. Dr. Paraskev Stoyanov”, 9002 Varna, Bulgaria

Department of Community Pharmacy, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, 41-200 Sosnowiec, Poland

Funding

the Medical University of Silesia in Katowice, Poland

References (31)

Show source-provided references
1. Inflammatory Bowel Disease Presentation and Diagnosis10.1016/j.suc.2019.08.001 ↗
2. Ulcerative Colitis and Crohn’s Disease Have Similar Burden and Goals for Treatment10.1016/j.cgh.2019.07.005 ↗
3. Ulcerative colitis or Crohn’s disease? Pitfalls and problems10.1111/his.12263 ↗
4. Targeting Specific Immunologic Pathways in Crohn’s Disease10.1016/j.gtc.2017.05.009 ↗
5. Gomez-Bris, R., Saez, A., Herrero-Fernandez, B., Rius, C., Sanchez-Martinez, H., and Gonzalez-Granado, J.M. (2023). CD4 T-Cell Subsets and the Pathophysiology of Inflammatory Bowel Disease. Int. J. Mol. Sci., 24.10.3390/ijms24032696 ↗
6. The influence of cytokines on the complex pathology of ulcerative colitis10.1016/j.autrev.2021.103017 ↗
7. TNF-α signalling and inflammation: Interactions between old acquaintances10.1007/s00011-013-0633-0 ↗
8. Ott, A., Tutdibi, E., Goedicke-Fritz, S., Schöpe, J., Zemlin, M., and Nourkami-Tutdibi, N. (2023). Serum cytokines MCP-1 and GCS-F as potential biomarkers in pediatric inflammatory bowel disease. PLoS ONE, 18.10.1371/journal.pone.0288147 ↗
9. Control of TH2 polarization by the chemokine monocyte chemoattractant protein-110.1038/35006097 ↗
10. Up-regulation of E-selectin and intercellular adhesion molecule-1 differs between Crohn’s disease and ulcerative colitis10.1007/BF02063969 ↗
11. Soluble selectins, sICAM, sVCAM, and angiogenic proteins in different activity groups of patients with inflammatory bowel disease10.1023/B:DDAS.0000037822.55717.31 ↗
12. P-selektyna i jej rola w niektórych chorobach
13. Interleukin 1α: A comprehensive review on the role of IL-1α in the pathogenesis and treatment of autoimmune and inflammatory diseases10.1016/j.autrev.2021.102763 ↗
14. Interleukin-1α Is a Central Regulator of Leukocyte-Endothelial Adhesion in Myocardial Infarction and in Chronic Kidney Disease10.1161/CIRCULATIONAHA.121.053547 ↗
15. Komosinska-Vassev, K., Kałużna, K., Jura-Półtorak, A., Derkacz, A., and Olczyk, K. (2022). Circulating Profile of ECM-Related Proteins as Diagnostic Markers in Inflammatory Bowel Diseases. J. Clin. Med., 11.10.3390/jcm11195618 ↗
16. The Crohn’s disease activity index (CDAI) is similarly elevated in patients with Crohn’s disease and in patients with irritable bowel syndrome10.1111/apt.12262 ↗
17. The Ulcerative Colitis Endoscopic Index of Severity More Accurately Reflects Clinical Outcomes and Long-term Prognosis than the Mayo Endoscopic Score10.1093/ecco-jcc/jjv210 ↗
18. IL-12, IL-23 and IL-17 in IBD: Immunobiology and therapeutic targeting10.1038/s41575-018-0084-8 ↗
19. Interleukin 12 is expressed and actively released by Crohn’s disease intestinal lamina propria mononuclear cells10.1016/S0016-5085(97)70128-8 ↗
20. Activation of NLRP3 Inflammasome in Inflammatory Bowel Disease: Differences Between Crohn’s Disease and Ulcerative Colitis10.1007/s10620-017-4609-8 ↗
21. Function and regulation of IL-1α in inflammatory diseases and cancer10.1111/imr.12615 ↗
22. Multipotent role of platelets in inflammatory bowel diseases: A clinical approach10.3748/wjg.v20.i12.3180 ↗
23. Response to infliximab therapy in ulcerative colitis is associated with decreased monocyte activation, reduced CCL2 expression and downregulation of Tenascin C10.1093/ecco-jcc/jju008 ↗
24. The role of TNFα in ulcerative colitis10.1177/0091270007301623 ↗
25. Neutrophil Extracellular Traps Sustain Inflammatory Signals in Ulcerative Colitis10.1093/ecco-jcc/jjy215 ↗
26. Adhesion to E-selectin primes macrophages for activation through AKT and mTOR10.1111/imcb.12447 ↗
27. Differential effects of anti-TNF-α and anti-IL-12/23 agents on human leukocyte-endothelial cell interactions10.1016/j.ejphar.2015.08.054 ↗
28. Tacrolimus (FK506) suppresses TNF-α-induced CCL2 (MCP-1) and CXCL10 (IP-10) expression via the inhibition of p38 MAP kinase activation in human colonic myofibroblasts10.3892/ijmm.2012.1094 ↗
29. Emerging Roles for Noncanonical NF-κB Signaling in the Modulation of Inflammatory Bowel Disease Pathobiology10.1097/MIB.0000000000000858 ↗
30. Interleukin-1α stimulates proinflammatory cytokine expression in human cardiac myofibroblasts10.1152/ajpheart.00372.2009 ↗
31. MAP kinases in inflammatory bowel disease10.1016/j.cca.2010.12.020 ↗